(Q28291250)

12 December 2020

Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use.

1 reference

12 December 2020

Pathophysiology of urticaria.

1 reference

12 December 2020

Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study.

1 reference

12 December 2020

In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1.

1 reference

12 December 2020

Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology

1 reference

12 December 2020

EAACI/GA2LEN/EDF guideline: management of urticaria.

1 reference

12 December 2020

Clinical advantages of dual activity in allergic rhinitis

1 reference

12 December 2020

Molecular and cellular mechanisms of allergic disease

1 reference

12 December 2020

Effects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac kv1.5 channels

1 reference

12 December 2020

Antihistamines in late-phase clinical development for allergic disease

1 reference

12 December 2020

Pharmacologic rationale for treating allergic and nonallergic rhinitis

1 reference

12 December 2020

Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF)

1 reference

12 December 2020

Chronic urticaria: pathogenesis and treatment

1 reference

12 December 2020

Rupatadine: a new selective histamine H1 receptor and platelet-activating factor (PAF) antagonist. A review of pharmacological profile and clinical management of allergic rhinitis

1 reference

12 December 2020

Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN).

1 reference

12 December 2020

Allergic rhinitis and its impact on asthma. In collaboration with the World Health Organization. Executive summary of the workshop report. 7-10 December 1999, Geneva, Switzerland

1 reference

12 December 2020

Rupatadine 10 mg and cetirizine 10 mg in seasonal allergic rhinitis: a randomised, double-blind parallel study.

1 reference

12 December 2020

Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers

1 reference

12 December 2020

Review of H1 antihistamines in the treatment of chronic idiopathic urticaria

1 reference

12 December 2020

Treatment for allergic rhinitis and chronic idiopathic urticaria: focus on oral antihistamines

1 reference

12 December 2020

Evaluation of the cardiac safety of second-generation antihistamines

1 reference

12 December 2020

A randomized, double-blind, parallel-group study, comparing the efficacy and safety of rupatadine (20 and 10 mg), a new PAF and H1 receptor-specific histamine antagonist, to loratadine 10 mg in the treatment of seasonal allergic rhinitis.

1 reference

12 December 2020

Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology.

1 reference

12 December 2020

Chronic urticaria: aetiology, management and current and future treatment options

1 reference

12 December 2020

Rupatadine: pharmacological profile and its use in the treatment of allergic disorders

1 reference

12 December 2020

Effects of rupatadine vs placebo on allergen-induced symptoms in patients exposed to aeroallergens in the Vienna Challenge Chamber

1 reference

12 December 2020

The safety and efficacy of desloratadine for the management of allergic disease

1 reference

12 December 2020

Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers

1 reference

12 December 2020

Chronic urticaria: a role for newer immunomodulatory drugs?

1 reference

12 December 2020

Safety and tolerability profiles of intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis

1 reference

12 December 2020

Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers

1 reference

12 December 2020

Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study

1 reference

12 December 2020

Sleep disturbances in allergic diseases.

1 reference

12 December 2020